OLHHA
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1258011-97-0
- 分子式: C27H45NO3
- 分子量:431.65
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-10863
Anandamide
-
HY-110016
Docosatetraenylethanolamide
-
HY-110004
ACEA
-
HY-113421
Linoleoyl ethanolamide
-
HY-139394
Arachidonoyl-1-thio-glycerol
-
HY-121517
URB754
-
HY-130567
1-Monoarachidin
-
HY-110003
Arachidonylcyclopropylamide
-
HY-112528
Glycerophospho-N-palmitoyl ethanolamine
-
HY-113070
Dihomo-γ-Linolenoyl Ethanolamide
-
HY-121476
Arachidonoyl Serinol
-
HY-124089S
Eicosapentaenoyl ethanolamide-d4
生物活性
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8- to 9-week-old male Zucker rats (genetic obesity)[2]
-
Dosage:5 mg/kg
-
Administration:I.p.; daily for 15 days
-
Result:Reduced the liver fat content and plasma triglyceride levels, and this was accompanied by a general improvement in the profile of plasma parameters related to liver damage in the obese rats, significantly reduced the body weight gain and decreased in the relative expression of CB1 in lean rats.
化学情報
-
CAS 番号 1258011-97-0
-
分子量 431.65
-
分子式 C27H45NO3
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(NC(C)CC1=CC=C(O)C(O)=C1)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Alen F, et al. PPARα/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. Biochem Pharmacol. 2018 Nov;157:235-243. [Content Brief]
[2]. Decara JM, et al. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. Dis Model Mech. 2015 Oct 1;8(10):1213-25. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
OLHHA 関連分類
HY-139230 関連分類
Powered by Bioz